查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771688

美國DNA 製造市場規模、佔有率和趨勢分析報告：按類型、等級、應用、最終用途和細分市場預測，2025 年至 2030 年

U.S. DNA Manufacturing Market Size, Share & Trends Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade (GMP & R&D), By Application (Cell & Gene Therapy, Vaccines, Oligonucleotide-based Drugs), By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國DNA 製造市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計到2030年，美國DNA製造市場規模將達到61.6億美元，預測期內的複合年成長率為18.27%。受個人化醫療、合成生物學和生物製藥產業擴張的推動，美國DNA製造業正經歷強勁成長。作為全球最大的生物技術創新中心，美國在DNA合成、基因編輯和治療開發等先進技術的採用方面處於領先地位。

酶促DNA合成、自動化寡核苷酸生產和連續製造系統等技術創新正在改變生產流程，使其更有效率、更具可擴展性。美國公司也大力投資無細胞DNA合成平台，以減少對傳統微生物系統的依賴，並縮短開發時間。

生物技術公司、學術機構以及受託製造廠商(CDMO) 之間的策略夥伴關係正在加速美國DNA 製造業的創新，並縮短產品上市時間。隨著基因和細胞治療、腫瘤診斷、感染疾病研究和疫苗開發等關鍵應用的擴展，對可擴展、高品質 DNA 解決方案的需求持續成長。因此，美國市場有望在精準醫療、下一代生物療法和尖端診斷技術的發展中發揮重要作用。

美國DNA 製造市場報告重點

  • 按類型分類，合成DNA在2024年佔據了美國DNA製造業的主導地位，佔收益佔有率的61.89%。此細分市場的成長得益於合成DNA在模組化生技藥品、客製化診斷和下一代疫苗平台中日益成長的應用。合成DNA適用於快速原型製作和進階篩檢，因為它可以在不依賴生物體的情況下創建複雜的序列。合成DNA在CRISPR工作流程、生物感測器開發和人工細胞系中日益重要的角色進一步鞏固了其在市場上的主導地位。
  • 從層級來看，隨著DNA治療方法臨床開發和商業應用的推進，GMP級DNA市場正在迅速擴張。嚴格遵守監管標準正促使製造商投資於品質保證系統、檢驗的製程和無塵室基礎設施。隨著越來越多的治療方法即將獲得FDA核准，GMP級DNA對於臨床試驗供應鏈、生產和生物製造規模化至關重要。
  • 從應用角度來看，細胞和基因治療在2024年佔據市場主導地位，佔43.81%的收入佔有率。這一領先地位歸因於病毒載體生產、基因有效載荷設計和細胞重編程通訊協定中對DNA輸入需求的激增。隨著針對癌症、血液疾病和神經系統疾病的療法不斷擴展，對精準、高品質DNA的需求持續推動該領域的成長。臨床階段計畫的投資也促進了DNA生產基礎設施的擴張。
  • 根據最終用途，製藥和生物技術公司將在2024年佔據49.08%的市場佔有率。這些公司越來越依賴DNA製造來進行產品線開發、疫苗創新和治療工程。為了縮短從發現到商業化的時間，該行業正在轉向專業的DNA供應商，以獲得客製化、可擴展且符合監管級別的解決方案。
  • 2025年5月，專注於核酸療法的受託製造廠商(CDMO) VGXI 宣布其位於德克薩斯州康羅的工廠已順利通過美國食品藥物管理局(FDA) 的檢查。這一里程碑使 VGXI 的客戶能夠提交涉及質體DNA（基因療法和 mRNA 疫苗的關鍵成分）臨床試驗的生技藥品核准申請 (BLA)。 VGXI 的成就彰顯了其在質體DNA 生產領域的領先地位，提供可擴展的高純度生產能力。 VGXI 是值得信賴的合作夥伴，致力於在全球範圍內推動改變生命的醫學研究和創新。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • DNA製造市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章美國DNA 製造市場：類型業務分析

  • 類型細分儀表板
  • 美國DNA 製造市場類型趨勢分析
  • 美國DNA 製造市場規模及趨勢分析（按類型）（2018-2030 年）
  • 質體DNA
  • 合成DNA

第5章美國DNA 製造市場：等級業務分析

  • 等級細分儀表板
  • 美國DNA製造市場等級波動分析
  • 美國DNA 製造市場規模與趨勢分析（按等級，2018-2030 年）
  • GMP級
  • 研發級

第6章美國DNA製造市場：應用業務分析

  • 應用程式細分儀表板
  • 美國DNA製造市場應用趨勢分析
  • 美國DNA 製造市場規模和趨勢分析（按應用，2018-2030 年）
  • 細胞和基因治療市場
  • 疫苗
  • 寡核苷酸藥物
  • 其他

第7章美國DNA 製造市場：最終用途業務分析

  • 最終用途細分儀表板
  • 美國DNA製造市場最終用途趨勢分析
  • 美國DNA 製造市場規模及趨勢分析（依最終用途），2018 年至 2030 年
  • 製藥和生物技術公司
  • 學術研究所
  • 合約研究組織

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
  • 2024年企業市場分析
  • 公司簡介/上市公司
    • Charles River Laboratories
    • VGXI, Inc.
    • Danaher（Aldevron）
    • . Thermo Fisher Scientific
    • Lonza
    • GenScript
    • Twist Bioscience
    • AGC Biologics
    • Catalent
    • Eurofins Genomics
Product Code: GVR-4-68040-630-1

U.S. DNA Manufacturing Market Growth & Trends:

The U.S. DNA manufacturing market size is projected to reach USD 6.16 billion by 2030, growing at a CAGR of 18.27% during the forecast period, according to a new report by Grand View Research, Inc. The U.S. DNA manufacturing industry is experiencing robust growth, driven by the expanding landscape of personalized medicine, synthetic biology, and the biopharmaceutical sector. As the largest hub for biotechnology innovation, the U.S. leads in adopting advanced technologies for DNA synthesis, gene editing, and therapeutic development.

Technological innovations such as enzymatic DNA synthesis, automated oligonucleotide production, and continuous manufacturing systems are transforming production processes, making them more efficient and scalable. U.S.-based companies also invest heavily in cell-free DNA synthesis platforms, which reduce dependency on traditional microbial systems and shorten development timelines.

Strategic partnerships among biotech firms, academic institutions, and Contract Development and Manufacturing Organizations (CDMOs) accelerate innovation and enable faster market entry in the U.S. DNA manufacturing industry. With critical applications spanning gene and cell therapies, oncology diagnostics, infectious disease research, and vaccine development, the demand for scalable, high-quality DNA solutions continues to grow. Consequently, the U.S. market is positioned to play a foundational role in advancing precision medicine, next-generation biotherapeutics, and cutting-edge diagnostics.

U.S. DNA Manufacturing Market Report Highlights:

  • By type, synthetic DNA dominated the U.S. DNA manufacturing industry in 2024, accounting for 61.89% of the revenue share. This segment's growth is driven by the rising use of synthetic DNA in modular biologics, customized diagnostics, and next-gen vaccine platforms. Its adaptability for producing complex sequences without relying on live organisms positions it as a preferred choice for rapid prototyping and advanced screening. The increasing role of synthetic DNA in CRISPR workflows, biosensor development, and engineered cell lines further supports its market dominance.
  • By grade, the GMP grade segment is expanding rapidly with the progression of DNA-based therapies into clinical development and commercial use. The requirement for strict compliance with regulatory standards is pushing manufacturers to invest in quality assurance systems, validated processes, and cleanroom infrastructure. As more therapies approach FDA approval, GMP-grade DNA is becoming essential for clinical trial supply chains, production, and biomanufacturing scale-up.
  • By application, cell and gene therapy led the market in 2024, capturing a 43.81% revenue share. This leadership stems from the surge in demand for DNA inputs in viral vector production, genetic payload design, and cell reprogramming protocols. As therapies targeting oncology, hematological disorders, and neurological diseases expand, the requirement for precise, high-quality DNA continues to drive segment growth. Investment in clinical-stage programs also contributes to the scaling of DNA production infrastructure.
  • By end use, pharmaceutical and biotechnology companies represented 49.08% of the market share in 2024. These companies increasingly rely on DNA manufacturing for pipeline development, vaccine innovation, and therapeutic engineering. With a focus on accelerating timelines from discovery to commercialization, the industry is turning to specialized DNA providers for customized, scalable, and regulatory-grade solutions.
  • In May 2025, VGXI, Inc., a contract development and manufacturing organization (CDMO) specializing in nucleic acid-based therapeutics, announced the successful completion of a U.S. Food and Drug Administration (FDA) inspection at its Conroe, Texas facility. This milestone enables VGXI's client to submit a Biologics License Application (BLA) for clinical trials involving plasmid DNA, a critical component in gene therapies and mRNA vaccines. VGXI's achievement underscores its leadership in plasmid DNA manufacturing, offering scalable and high-purity production capabilities. The company has been a trusted partner in advancing life-changing medical research and innovation worldwide.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Grade Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. DNA Manufacturing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. DNA Manufacturing Market: Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. DNA Manufacturing Market Type Movement Analysis
  • 4.3. U.S. DNA Manufacturing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Plasmid DNA
    • 4.4.1. U.S. Plasmid DNA-based Market, 2018 - 2030 (USD Million)
  • 4.5. Synthetic DNA
    • 4.5.1. U.S. Synthetic DNA Market, 2018 - 2030 (USD Million)
      • 4.5.1.1. Gene Synthesis
        • 4.5.1.1.1. U.S. Synthetic DNA Market, 2018 - 2030 (USD Million)
      • 4.5.1.2. Oligonucleotide Synthesis
        • 4.5.1.2.1. U.S. Synthetic DNA Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. DNA Manufacturing Market: Grade Business Analysis

  • 5.1. Grade Segment Dashboard
  • 5.2. U.S. DNA Manufacturing Market Grade Movement Analysis
  • 5.3. U.S. DNA Manufacturing Market Size & Trend Analysis, by Grade, 2018 to 2030 (USD Million)
  • 5.4. GMP Grade
    • 5.4.1. U.S. GMP Grade Market, 2018 - 2030 (USD Million)
  • 5.5. R&D Grade
    • 5.5.1. U.S. R&D Grade Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. DNA Manufacturing Market: Application Business Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. U.S. DNA Manufacturing Market Application Movement Analysis
  • 6.3. U.S. DNA Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Cell & Gene Therapy Market
    • 6.4.1. U.S. Cell & Gene Therapy Market, 2018 - 2030 (USD Million)
  • 6.5. Vaccines
    • 6.5.1. U.S. Vaccines Market, 2018 - 2030 (USD Million)
  • 6.6. Oligonucleotide-based drugs
    • 6.6.1. U.S. Oligonucleotide-based drugs Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. U.S. Others Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. DNA Manufacturing Market: End Use Business Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. U.S. DNA Manufacturing Market End Use Movement Analysis
  • 7.3. U.S. DNA Manufacturing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Pharmaceutical and Biotechnology Companies
    • 7.4.1. U.S. Pharmaceutical and Biotechnology Companies Devices Market, 2018 - 2030 (USD Million)
  • 7.5. Academic & Research Institutes
    • 7.5.1. U.S. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 7.6. Contract Research Organizations
    • 7.6.1. U.S. Contract Research Organizations Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Charles River Laboratories
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Service Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. VGXI, Inc.
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Service Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Danaher (Aldevron)
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Service Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. . Thermo Fisher Scientific
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Service Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Lonza
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Service Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. GenScript
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Type Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Twist Bioscience
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Service Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. AGC Biologics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Service Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Catalent
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Service Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Eurofins Genomics
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Service Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 U.S. DNA manufacturing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. DNA manufacturing market estimates & forecasts, by grade, 2018 - 2030 (USD Million)
  • Table 5 U.S. DNA manufacturing market estimates & forecasts, by application type, 2018 - 2030 (USD Million)
  • Table 6 U.S. DNA manufacturing market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 PESTLE Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 U.S. DNA Manufacturing market: Type outlook key takeaways
  • Fig. 13 U.S. DNA Manufacturing market: Type movement analysis
  • Fig. 14 Plasmid DNA market, 2018 - 2030 (USD million)
  • Fig. 15 Synthetic DNA market, 2018 - 2030 (USD million)
  • Fig. 16 U.S. DNA Manufacturing market: Grade outlook key takeaways
  • Fig. 17 U.S. DNA Manufacturing market: Grade movement analysis
  • Fig. 18 GMP Grade market, 2018 - 2030 (USD million)
  • Fig. 19 R&D Grade market, 2018 - 2030 (USD million)
  • Fig. 20 U.S. DNA Manufacturing market: Application outlook key takeaways
  • Fig. 21 U.S. DNA Manufacturing market: Application movement analysis
  • Fig. 22 Cell & Gene Therapy market, 2018 - 2030 (USD million)
  • Fig. 23 Vaccines market, 2018 - 2030 (USD million)
  • Fig. 24 Oligonucleotide-based drugs market, 2018 - 2030 (USD million)
  • Fig. 25 Others market, 2018 - 2030 (USD million)
  • Fig. 26 U.S. DNA Manufacturing market: End Use outlook key takeaways
  • Fig. 27 U.S. DNA Manufacturing market: End Use movement analysis
  • Fig. 28 Pharmaceutical and Biotechnology Companies market, 2018 - 2030 (USD Million)
  • Fig. 29 Contract Research Organizations market, 2018 - 2030 (USD Million)
  • Fig. 30 Academic & Research Institutes market, 2018 - 2030 (USD Million)
  • Fig. 31 Key companies profiled